Still Investors' Cup Of Tea
Snapple Beverage, whose stock short-sellers love to hate, keeps dodging brickbats. The latest is a Food & Drug Administration inquiry into whether its iced teas and fruit drinks are made from the natural ingredients it claims. When the news of the probe broke in mid-October, the stock lost two points, going to 23. (Snapple went public last December at 8.) But the FDA tells BUSINESS WEEK it has ended the investigation without taking action. A similar probe by California regulators is expected to be called off, too.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- As Bitcoin Sinks, Crypto Bros Party Hard on a Blockchain Cruise
- Norwegian Airlines Sets Record for Fastest Transatlantic Flight
- Amazon Go Pushes Mediterranean Lamb, Skips the Chili Cheese Dogs
- How a 22-Year-Old Discovered the Worst Chip Flaws in History
- OPEC, Russia Signal Global Oil Alliance May Endure Past 2018